Charles River Laboratories Intl. Inc vs Enphase Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while Enphase Energy Inc trades at $32.12 (market cap $4.35B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.3× Enphase Energy Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Enphase Energy Inc for 72 Days on average.
| CRL | ENPH | |
|---|---|---|
Market Cap | $14.23B | $4.35B |
Volume | 1,176,885 | 5,068,595 |
Sector | Health | Energy |
52-Week High | $310.77 | $72.33 |
52-Week Low | $149.93 | $26.12 |
Typical Hold Time | 33 Days | 72 Days |
Enterprise Value | $17.06B | $3.99B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Enphase Energy (ENPH) trades at $33.50, down 1.21% with bearish technical signals and mixed earnings performance. The stock shows declining revenue from $2.3B in 2023 to $1.47B in 2025, though net margins improved to 10.09%. Recent developments include IQ Meter Collar approvals and solid-state transformer production for AI data centers, providing potential growth catalysts amid solar sector volatility.
Outlook remains cautious with analyst consensus at $42.90 (28% upside) but recent earnings misses and high borrowing costs for solar projects pose near-term risks. The stock offers exposure to energy technology innovation but faces competitive pressure and macroeconomic headwinds affecting renewable energy demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →